Search results
21 mar 2023 · Adoptive immunotherapy targeting Epstein–Barr virus has emerged as a potential therapeutic strategy for the treatment of multiple sclerosis. We have developed a novel manufacturing process, which can offer these T‐cell therapies as an off‐the‐shelf treatment. Introduction.
Role of Epstein-Barr virus in the development of MS EBV triggers MS by molecular mimicry, promoting memory B cells that function as pro-inflammatory antigen-presenting cells for T cells and by establishing a latent infection in B cells.
17 gru 2020 · In line with the model of EBV’s role in MS, new treatments based on monoclonal antibodies (MAbs) targeting B cells have shown good efficacy in clinical trials both for RRMS and PPMS, while...
11 mar 2022 · Epstein-Barr virus (EBV) is a putative trigger for multiple sclerosis (MS). Bjornevik et al. utilized longitudinal analysis of 10 million adults to strongly link MS to EBV infection1 and Lanz et al. identified clonally expanded B cells in MS that bind EBV EBNA1 and GlialCam.2
7 lut 2023 · Multiple sclerosis is a chronic inflammatory disease of the CNS that results from the interplay between heritable and environmental factors. Mounting evidence from different fields of research supports the pivotal role of the Epstein-Barr virus (EBV) in the development of multiple sclerosis.
9 lut 2023 · In the first approach, monoclonal antibodies (mAbs) to CD20 are used to kill B cells that harbour latent EBV infection; such mAbs have been approved to treat patients with MS. Targeting of...
Autoimmune cross-reaction of specific antibodies to Epstein-Barr virus (EBV) has been associated with development of multiple sclerosis (MS). In this issue of Cell, Vietzen et al. identify additional immunological regulatory mechanisms that protect against autoimmunity in healthy people but are reduced in MS cases.
